NCT06284408 Centralized Screening Unit (CSU) at Montefiore-Einstein
| NCT ID | NCT06284408 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Albert Einstein College of Medicine |
| Condition | Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 9,460 participants |
| Start Date | 2025-02-24 |
| Primary Completion | 2029-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 9,460 participants in total. It began in 2025-02-24 with a primary completion date of 2029-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study proposes to increase Lung-cancer screening (LCS) in the Bronx, New York. Despite strong evidence that Lung-cancer screening (LCS) can reduce Lung cancer (LCa) deaths, low-dose computed tomography (LDCT) referral rates by clinicians are very low and there is poor adherence with LCS by patients. Both provider and patient barriers may be amenable to systemic improvements in support, coordination and infrastructure for screening. The investigator team hypothesizes that the implementation of a Central Screening Unit (CSU) that shifts routine workflow attributed to LCS (e.g., collection of smoking history, determination of eligibility, shared decision making and arranging follow-up) away from busy practices (usual care) and that offers patients an array of navigation and support services will increase the uptake of LCS guidelines and subsequent low-dose computed tomography (LDCT) screening scans in a low-income, predominately Hispanic and Black catchment area. The proposed study represents a unique opportunity to test this hypothesis in the context of the roll out of a CSU as a significant new component of the Montefiore-Einstein health system. The investigator team will examine whether and how the CSU facilitates LCS uptake and retention of patients. This study is powered to test whether CSU reduces proportion of late-stage lung cancer diagnoses in the Bronx, New York.
Eligibility Criteria
Inclusion Criteria: Clinic level: * a NYC RING affiliated clinic, * Opt into and agree to research protocol; Patient level: * Age 50-77 for participants, * past or current smoker, * 20+ pack-years tobacco, * has quit smoking within the last 15 years, * without chest CT within the past 12 months, and, * no history of lung cancer or and at least 5 years since the diagnosis of any other malignancy Exclusion Criteria: Clinic level: * only treats pediatric patients, * Opt out of research protocol; Patient level: * Primary care provider instruction to not contact an individual for any reason. Any individual inadvertently contacted who does not meet these criteria will be excluded from the study.
Contact & Investigator
H. Dean Hosgood, PhD
PRINCIPAL INVESTIGATOR
Albert Einstein College of Medicine
Frequently Asked Questions
Who can join the NCT06284408 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 77 Years, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06284408 currently recruiting?
Yes, NCT06284408 is actively recruiting participants. Contact the research team at dean.hosgood@einsteinmed.edu for enrollment information.
Where is the NCT06284408 trial being conducted?
This trial is being conducted at The Bronx, United States.
Who is sponsoring the NCT06284408 clinical trial?
NCT06284408 is sponsored by Albert Einstein College of Medicine. The principal investigator is H. Dean Hosgood, PhD at Albert Einstein College of Medicine. The trial plans to enroll 9,460 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.